| Literature DB >> 34205002 |
Róbert Berkecz1, Dániel Tanács1, Antal Péter1, István Ilisz1.
Abstract
Numerous chemical compounds of high practical importance, such as drugs, fertilizers, and food additives are being commercialized as racemic mixtures, although in most cases only one of the isomers possesses the desirable properties. As our understanding of the biological actions of chiral compounds has improved, the investigation of the pharmacological and toxicological properties has become more and more important. Chirality has become a major issue in the pharmaceutical industry; therefore, there is a continuous demand to extend the available analytical methods for enantiomeric separations and enhance their efficiency. Direct liquid chromatography methods based on the application of chiral stationary phases have become a very sophisticated field of enantiomeric separations by now. Hundreds of chiral stationary phases have been commercialized so far. Among these, macrocyclic glycopeptide-based chiral selectors have proved to be an exceptionally useful class of chiral selectors for the separation of enantiomers of biological and pharmacological importance. This review focuses on direct liquid chromatography-based enantiomer separations, applying macrocyclic glycopeptide-based chiral selectors. Special attention is paid to the characterization of the physico-chemical properties of these macrocyclic glycopeptide antibiotics providing detailed information on their applications published recently.Entities:
Keywords: chiral stationary phases; enantiomer separations; liquid chromatography; macrocyclic glycopeptide antibiotics
Mesh:
Substances:
Year: 2021 PMID: 34205002 PMCID: PMC8199854 DOI: 10.3390/molecules26113380
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Summary of the physico-chemical properties of macrocyclic antibiotics applied as chiral selectors [13].
| Properties | Ansamycins | Glycopeptides | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Rifampicin | Rifamycin B | Rifamycin SV | Avoparcin | Teicoplanin A2–2 | Teicoplanin A-40,926 | Teicoplanin MDL 63,246 | Dalbavancin | ||
| Molecular weight | 823 | 756 | 698 | α = 1908 | 1877 | B0 = 1732 | 1789 | 1817 | |
| Hydrophobic tail | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | |
| Number of … | asymmetric centers | 9 | 9 | 9 | 32 | 23 | B0 = 19 | 18 | 18 |
| macrocycles | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | |
| aromatic rings | 2 | 2 | 2 | 7 | 7 | 7 | 7 | 7 | |
| sugar moieties | 0 | 0 | 0 | 5 | 3 | 2 | 2 | 2 | |
| hydroxy groups | 5 | 5 | 5 | 16 | 14 | 11 | 12 | 11 | |
| primary amines | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | |
| secondary amines | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | |
| amido groups | 1 | 1 | 1 | 6 | 8 | 7 | 8 | 8 | |
| carboxylic groups | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | |
| methoxy groups | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| methyl esters | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Produced by |
|
|
|
|
|
| Synthetic compound | Synthetic compound | |
Summary of the physico-chemical properties of macrocyclic antibiotics applied as chiral selectors [13].
| Properties | Glycopeptides | Polypeptides | ||||||
|---|---|---|---|---|---|---|---|---|
| Teicoplanin Aglycone | Ristomycin Ristocetin A | Vancomycin | Nor-Vancomycin | Eremomycin | Balhimycin | Thiostrepton | ||
| Molecular weight | 1197 | 2066 | 1449 | 1435 | 1558 | 1446 | 1665 | |
| Hydrophobic tail | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Number of … | asymmetric centers | 8 | 38 | 18 | 18 | 22 | 17 | 17 |
| macrocycles | 4 | 4 | 3 | 3 | 3 | 3 | 2 | |
| aromatic rings | 7 | 7 | 5 | 5 | 5 | 5 | 1 | |
| sugar moieties | 0 | 6 | 2 | 2 | 3 | 2 | 0 | |
| hydroxy groups | 7 | 21 | 9 | 9 | 9 | 8 | 5 | |
| primary amines | 1 | 2 | 1 | 2 | 3 | 1 | 0 | |
| secondary amines | 0 | 0 | 1 | 0 | 0 | 1 | 1 | |
| amido groups | 6 | 6 | 7 | 7 | 7 | 7 | 11 | |
| carboxylic groups | 1 | 0 | 1 | 1 | 1 | 1 | 0 | |
| methoxy groups | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| methyl esters | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Produced by |
|
|
|
|
|
|
| |
Figure 1Structure of ansamycins.
Figure 2Structure of glycopeptides and polypeptides.
Enantioseparation of stereoisomers of different analytes on vancomycin- and vancomycin-related analog-based CSPs 1.
| Analytes | Selectors | Column’s Trade Mark | The Most Effective Mobile Phases ( | Mode | Reference |
|---|---|---|---|---|---|
| trantinterol | Vancomycin | Chirobiotic V | MeOH/MeCN/AcOH/NH4OH 80/20/0.02/0.01 or 60/40/0.02/0.01 | PIM | [ |
| amphetamine, metamphetamine | Vancomycin | Chirobiotic V | MeOH/AcOH/NH4OH 100/0.1/0.02 | PIM | [ |
| amphetamine, metamphetamine, methylenedioxyamphetamine, methorphan, methylenedioxymetamphetamine, ephedrine, pseudoephedrine | Vancomycin | Chirobiotic V2 | MeOH/0.04% NH4TFA | PIM | [ |
| ketoprofen | Vancomycin | chiral mobile phase additive | 0.05 M KH2PO4 (pH 6.0)/2-propanol 50/50/ | RPM | [ |
| amlodipin, atropine, baclofen, ibuprofen, mandelic acid, Phe | Vancomycin degradation product | tailor-made | 0.1% NH4TFA in MeOH | PIM | [ |
| metoprolol, pindolol, alprenolol, oxprenolol, labetolol, atenolol | immobilized mixed Eremomycin and Vancomycin on silica | tailor-made | 0.1% aq.TEAA (pH 4.5)/MeOH/MeCN (5/20/75) | RPM | [ |
| Β-blockers: nadolol, atenolol, metoprolol, alprenolol, oxprenolol, pindolol | Vancomycin on gold nanoparticles | tailor-made | 25 mM potassium phosphate (pH 4)/MeCN (96/4) | RPM | [ |
| mandelic acid, propranolol | Vancomycin | tailor-made | NPM | [ | |
| chiral xanthone derivatives | Vancomycin, Teicoplanin, Teicoplanin aglycone, Ristocetin A | Chirobiotic V | NPM | [ | |
| nine aromatic hydroxy acids | Eremomycin | Nautilus-E | aq. NH4OAc (pH 3.3–6.3)/EtOH (60/40) | RPM | [ |
| ketoprofen, flurbiprofen, suprofen, carprofen, ibuprofen, warfarin | Clindamycin phosphate (CLIP) and Erythromycin incorporated to zircona hybrid monolith | CLIP-ZHM | MeOH/MeCN (20/80) containing 300 mM AcOH and 10 mM TEA | CEC | [ |
| atenolol, chlorphenamine, esmelol, nefopam, propranolol | azithro-mycin lactobionate, clindamycin phosphate | tailor-made | freshly dissolved azithro-mycin lactobionate and clindamycin phosphate in phosphate buffer (20 mM) adjusted to specific pH with sodium hydroxide | CEC | [ |
1 RPM, reversed-phase mode; NPM, normal phase mode; PIM, polar-ionic mode; POM, polar-organic mode; CEC, capillary electrochromatography.
Enantioseparation of stereoisomers of different analytes on teicoplanin, teicoplanin aglycon, vancomycin and on ristocetin A-based CSPs.
| Group of Racemates | Racemates | Selector | Column’s Trade Mark | The Most Effective Mobile Phase ( | Mode | Reference |
|---|---|---|---|---|---|---|
| Amino acids | phenylisoserine derivatives | Teicoplanin | Chirobiotic T | 0.1% TEAA (pH 4.1)/MeOH (50/50) | RPM | [ |
| Met, Cys, homo-Cys | Teicoplanin | Chirobiotic T | 25 mM aq. phosphate buffer/1 mM aq. octanesulfonic acid (pH 2.7)/MeCN/MeOH (94/3/3) | RPM | [ | |
| therapeutic peptides | Teicoplanin, Vancomycin | Chirobiotic T | 20 mM aq. NH4OAc (pH 4.1)/MeCN (5/95) | HILIC | [ | |
| carbocyclic β-amino acids possessing limonene skeleton | Teicoplanin | Chirobiotic T | MeOH/AcOH/TEA (100/0.01/0.01) | PIM | [ | |
| Phe | Teicoplanin | Chirobiotic T | MeCN/H2O (75/25) | RPM | [ | |
| Drugs | ofloxacin | Teicoplanin | Chirobiotic T | 0.45% aq. TEAA (pH 3.6)/EtOH (20/80) | RPM | [ |
| epimeric mixtures of fortimicin aminoglycosides | Teicoplanin | Chirobiotic T | 10 mM ammonium formate/MeOH | PIM | [ | |
| citalopram analogs | Teicoplanin | Chirobiotic T | 0.1% aq. TEAA (pH 4.1)/MeOH | RPM | [ | |
| modafanil | Teicoplanin | Chirobiotic T | MeOH/TEA (100/0.05) | PIM | [ | |
| Drugs | ibuprofen, carboxyibuprofen, 2-hydroxy ibuprofen, chloramphenicol, ifosfamide, indoprofen, ketoprofen, naproxen, praziquantel | Teicoplanin | Chirobiotic T | aq. 10 mM NH4OAc (pH 4.2)/MeOH (70/30) | RPM | [ |
| Drugs | mandelic acid, vanylmandelic acid, phenyllactic acid | Teicoplanin + ionic liquids | Chirobiotic T | MeOH/H2O + borneol or fenchol-based ionic liquids | RPM | [ |
| albuterol | Teicoplanin aglycon | Chirobiotic TAG | MeOH/MeCN/TEA/AcOH (90/10/0.05/0.05) | PIM | [ | |
| tofisopam | Teicoplanin | Chirobiotic T | 0.1% TEAA (pH 4.1)/MeOH | RPM | [ | |
| primaquine, tafenoquine, flumequine, lomefloxacine, ofloxacin, qunacrine | Teicoplanin | Chirobiotic T | MeOH/MeCN/water/TEA (70/10/20/0.01); (60/30/10/0.1) and (50/30/20/01) | PIM | [ | |
| primaquine, quinacrine, tafenoquine | Ristocetin A | Chirobiotic R | MeOH/MeCN/water/TEA (70/10/20/0.1); (60/30/10/0.1) | PIM | [ | |
| carnosine | Teicoplanin | Chirobiotic T | aq. formic acid/MeOH (80/20–20/80), pHa 3.1–3.8 | RPM | [ | |
| pyrroloquinolo-ne analogs | Ristocetin A | Nautilus-R | water/MeCN (65/35) | RPM | [ | |
| pantoprazole | Teicoplanin aglycon | Chirobiotic TAG | aq. 20 mM NH4OAc/MeOH (40/60) | RPM | [ | |
| Leu–Leu, Gly–Leu, Leu–Gly | Teicoplanin | Chirobiotic T | aq. 0.097 M AcOH + 0.003 M NH4OAc (pH 3.85)/MeCN | RPM | [ | |
| Peptides | Ala–Ala, Leu–Leu, Gly–Leu, Leu–Gly | Ristocetin A | Chirobiotic R | aq. 0.0002 M NH4OAc/MeOH (100/0–10/90) | RPM | [ |
| Leu–Leu, Gly–Gly | Ristocetin A | Chirobiotic R | aq. 0.0002 M NH4OAc/MeOH (90/10) | RPM | [ | |
| Ala–Ala, Gly–Leu, Leu–Gly | Ristocetin A | Chirobiotic R | aq. 100 mM NH4OAc/MeOH (60/40) | RPM | [ | |
| Phe, Tyr, Trp | Teicoplanin | Chirobiotic T2 | CO2/(MeOH/water) 60/(90/10) | SFC | [ | |
| Miscellenous | 67 racemates: amino acids, β-blockers, profens, pesticides, etc. | Teicoplanin | Chirobiotic T | CO2/MeOH 90/10; CO2/MeOH (90/10) + 0.1% formic acid or diethylamine in CO2 | SFC | [ |
Ultra-high-performance liquid chromatographic enantioseparations of different analytes on macrocyclic glycopeptide selectors immobilized on sub-2 µm superficially porous (core-shell) and fully porous particles.
| Racemates | Selector | Column Characteristics | The Most Effective Mobile Phase | Mode | Reference |
|---|---|---|---|---|---|
| 60 pairs of enantiomers of: amino acids, peptides, primary amines, β-blockers, thalidomide, nicardipine, proglumide, coumachlor, warfarin, mianserin, etc. | Teicoplanin | TeicoShell, SPP, 2.7-μm | water/MeOH (99/1–10/90) | RPM | [ |
| amino acids, β-blockers, oxazolidinones, mandelic acid, coumachlor, proglumide, thalidomide, warfarin, mianserin | Teicoplanin | Titan-T, FPP-NPSD, 1.9-μm | NPM | [ | |
| Met, Val, Leu, Ala, Nval, Nleu | Teicoplanin | SPP, sub-2-μm | EtOH/water (80/20) and (90/10) | RPM | [ |
| DNPyr–Leu, DNPyr–Nval, | Teicoplanin | SPP, 2.7-μm | 100% MeOH | POM | [ |
| fluorinated, desfluorinated analytes: ofloxacin, cipro-floxacin, ezitimibe, paro-xetine, voriconazole, aprepitant, atorvastatin | Teicoplanin | TeicoShell, SPP, 2.7-μm VancoShell, SPP, 2.7-μm | MeOH/MeCN/TFA/TEA (10/90/0.3/0.2) | PIM | [ |
| enkephalin, bradykinin, vasopressin, LHRH peptides | Teicoplanin | TeicoShell, SPP, 2.7-μm | 2.5–50 mM NH4HCOO (pH 3.2)/MeCN/ (65/35, 30/70) | RPM | [ |
| nicotine | modified teicoplanin | NicoShell, SPP, 2.7-μm | 0.1% ammoniumtrifluoro acetate in MeOH | RPM | [ |
| tobacco alkaloids | Teicoplanin | TeicoShell, SPP, 2.7-μm | 0.025–0.5 wt% HCOONH4 in MeOH | PIM | [ |
| Teicoplanin | zwitterionic phases | 20 mM aq. NH4OAc/MeOH (15/85) | RPM | [ | |
| 2-(4-chloro-phenoxy)-propionic acid | Teicoplanin | zwitterionic phases | aq. 20 mM HCOONH4 (pH 7.5)/MeCN (15/85) | HILIC | [ |
| haloxyfop, ketolarac, ketoprofen, indoprofen, flunoxaprofen, naproxen, suprofen, ibuprofen, Fmoc-, Boc-, Z-, danzyl-amino acids | Teicoplanin | zwitterionic phases | aq. 10 mM HCOONH4 (pH 6.5)/MeOH (15/85) | RPM | [ |
| 4-, 6-, 7-, 8- and 10-hydroxywarfarins, | Teicoplanin | 2D-LC | aq. 5% H3PO4/MeCN 95/5 | RPM | [ |
| intermediates of verubecestat synthesis | Teicoplanin | TeicoShell, SPP, 2.7-μm | aq. 0.1% H3PO4/MeCN (70/30) | RPM | [ |
| 150 primary-, secondary- and tertiary-amines | Vancomycin | VancoShell, SPP, 2.7-μm | aq. NH4TFA/MeOH; aq. HCOONH4/MeOH; aq. HCOONH4/MeCN; aq. HCOONH4/EtOH; MeOH/AcOH/NH4OH; MeOH/MeCN/AcOH/TEA; | RPM | [ |
| amines, amino acids and derivatives; non-steroidal anti-inflammantory drugs, pesticides, nicotine and metabolites | Vancomycin (EDP) | EDP, SPP, 2.7-μm | 0.1 wt% HCOONH4 in MeOH | PIM | [ |
| 100 pesticides: pyrethroids, fungicides, organophosphates, acylanilides, herbicides, rodenticides, etc. | Teicoplanin | TeicoShell, SPP, 2.7-μm | 0.025–0.5 wt% HCOONH4 in MeOH | PIM | [ |
| azole compounds: oxazols, thiazols | Teicoplanin | TeicoShell, SPP, 2.7-μm | aq. 20 mM HCOONH4 (pH 3–4)/MeOH (85/15–50/50) | RPM | [ |
| 100 chiral analytes: amines, derivatized amino acids, nicotine and metabolites, β-blockers, pesticides, drugs etc., | Teicoplanin | TeicoShell, SPP, 2.7-μm | 0.1% TEA in MeOH/CO2 (25/75) | SFC | [ |
| cis-4,5-diphenyl-2-oxazo-lidinone, 2-(4-chloro-phenoxy)propionic acid, fluoxetine, nicardipine, bupivacaine, roglumide | Teicoplanin | TeicoShell, SPP, 2.7-μm | MeOH/CO2 (5/95) | SFC | [ |
| phytoalexins, substituted tryptophanes, ketamine derivatives | Teicoplanin | TeicoShell, SPP, 2.7-μm | 0.05–0.1% DEA, TEA, TFA or 2-propylamine in MeOH, EtOH, 2-PrOH or 1-PrOH/CO2 (20/80; 60/40; 5/95) | SFC | [ |
| cis-4,5-diphenyl-2-oxazolidinone, chlorthalidone, 5,5-diphenyl-4-benzyl-2-oxazolidinone, nicotine, bupivacaine, prilocaine, tranylcypromine, amphetamine, venlafaxine, tryptophan, 1,2,2-triphenylethylamine, 2-chloro-indan-1-ylamine, disopyramide, tetramisole, fenoprofen | Teicoplanin | TeicoShell, SPP, 2.7-μm | “190” EtOH/CO2 (20/80; 25/75) | SFC | [ |